Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

A new study reveals that semaglutide, a common diabetes medication, may effectively treat fatty liver disease, offering hope ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...